Hematologic Malignancy
B-Cell Neoplasm
CI-CAN-00000470Explore in graph →
HematologicNon-malignant2,097 active trials46 approved drugs301 evidence items
- NCIt
- C27907
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000470Explore in graph →
Clinical trials
7,500 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06357988 | Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) | active not recruiting | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT06360575 | Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 |
| clinicaltrials |
| NCT06400238 | Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT01351896 | Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | May 27, 2026 | clinicaltrials |
| NCT04439149 | Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) | active not recruiting | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | May 27, 2026 | clinicaltrials |
| NCT04439188 | Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 27, 2026 | clinicaltrials |
| NCT06458439 | Epcoritamab-CAR T Cells for Large B-cell Lymphomas | recruiting | Phase 2 | 31 | Abramson Cancer Center at Penn MedicineOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT06566547 | GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma | active not recruiting | Phase 2 | 116 | Genrix (Shanghai) Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT06954805 | Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD) | recruiting | Phase 2 | 30 | Jennifer AmengualOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07608978 | Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes(Pola-ZRCHP) | recruiting | Phase 2 | 35 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT03598998 | Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | active not recruiting | Phase 1 / Phase 2 | 13 | City of Hope Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT05480449 | Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) | recruiting | Phase 1 / Phase 2 | 115 | Stephan Grupp MD PhDOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT00869232 | UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission | active not recruiting | Phase 2 | 90 | University of ArkansasOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT02427620 | Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma | active not recruiting | Phase 2 | 131 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05783609 | Epcoritamab and Rituximab for First-line Follicular Lymphoma | recruiting | Phase 2 | 100 | Reid Merryman, MDOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT02877303 | Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04302324 | A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab | active not recruiting | Phase 2 | 11 | Weill Medical College of Cornell UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05190705 | Loncastuximab Tesirine in WM | active not recruiting | Phase 2 | 21 | Shayna Sarosiek, MDOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07600151 | Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma(CONQUISTADOR) | not yet recruiting | Phase 1 / Phase 2 | 220 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT03710772 | Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | active not recruiting | Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT04649359 | MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb | active not recruiting | Phase 2 | 187 | PfizerINDUSTRY | 8 | May 19, 2026 | clinicaltrials |
| NCT06588478 | A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | recruiting | Phase 2 | 249 | Loxo Oncology, Inc.INDUSTRY | 18 | May 19, 2026 | clinicaltrials |
| NCT02797470 | Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 11 | AIDS Malignancy ConsortiumNETWORK | 1 | May 18, 2026 | clinicaltrials |
| NCT04661007 | To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)(J-MIND) | active not recruiting | Phase 1 / Phase 2 | 72 | Incyte Biosciences Japan GKINDUSTRY | 1 | May 18, 2026 | clinicaltrials |
| NCT04941716 | Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial | recruiting | Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05853965 | Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma(BELI(E)VE) | recruiting | Phase 1 / Phase 2 | 45 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06005870 | Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression | recruiting | Phase 2 | 41 | Huazhong University of Science and TechnologyOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07593482 | Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.(FC-BALANCE) | not yet recruiting | Phase 2 | 92 | Swiss Cancer InstituteOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT03104842 | Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone | active not recruiting | Phase 2 | 246 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05221645 | Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma(P+R-ICE) | active not recruiting | Phase 2 | 65 | University of SouthamptonOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06867536 | Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden(GLOHRT-01) | recruiting | Phase 2 | 40 | Liling ZhangOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04458610 | Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07585747 | A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide(CUREMZL002) | not yet recruiting | Phase 2 | 27 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05002816 | Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 24 | Yale UniversityOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05497804 | Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial | active not recruiting | Phase 2 | 17 | Mayo ClinicOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05514990 | Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial | active not recruiting | Phase 1 / Phase 2 | 10 | University of Southern CaliforniaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05828511 | A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment(LINKER-MM4) | recruiting | Phase 1 / Phase 2 | 149 | Regeneron PharmaceuticalsINDUSTRY | 3 | May 13, 2026 | clinicaltrials |
| NCT06385496 | Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT06390865 | Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) | active not recruiting | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT06400225 | Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT06504199 | Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma(ZGR) | active not recruiting | Phase 2 | 39 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06993675 | Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)(ROTATE) | recruiting | Phase 2 | 50 | Noffar BarOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07259070 | Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07261163 | Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma | recruiting | Phase 2 | 37 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07299149 | Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma(ZGR in TN FL) | recruiting | Phase 2 | 34 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07517705 | MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 2 | 50 | University of NebraskaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07584889 | Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies(CAR-p40-T) | recruiting | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT03038672 | Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas | active not recruiting | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | May 12, 2026 | clinicaltrials |
| NCT04263480 | Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia(CZAR-1) | active not recruiting | Phase 2 | 99 | Christian BuskeOTHER | 3 | May 12, 2026 | clinicaltrials |
| NCT06852638 | CD70-targeted immunoPET Imaging of Malignant Cancers | recruiting | Phase 2 | 300 | RenJi HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 28, 2026source: clinicaltrials